日本前瞻性队列的全面甲状腺评估:甲状腺功能、自身免疫及超声表现的横断面基线分析
该研究为日本京都大学医院前瞻性队列的横断面基线分析,纳入4407名无已知甲状腺疾病的体检成人,整合甲状腺功能、超声、FDG-PET及TPOAb检测。结果显示甲状腺功能障碍、超声血流增加、弥漫性甲状腺FDG摄取和甲状腺结节的患病率分别为5.8%、2.5%、3.4%和39.7%,女性均更常见;TPOAb滴度≥128 IU/mL与并发甲状腺功能障碍及异常相关。
要点
- 女性甲状腺功能障碍、超声血流增加、弥漫性FDG摄取及结节患病率均高于男性。
- TPOAb滴度≥128 IU/mL与并发甲状腺功能障碍、血流增加及弥漫性FDG摄取相关。
- 年龄、性别和甲状腺体积为甲状腺功能的主要决定因素。
核心结论
- 整合甲状腺功能、超声、FDG-PET和TPOAb的综合评估可提供甲状腺健康的流行病学和生理学见解。
- TPOAb滴度较高与并发甲状腺功能障碍和异常相关,年龄、性别和甲状腺体积为甲状腺功能的主要决定因素。
- 严格定义的健康队列使得建立性别特异性甲状腺尺寸参考范围成为可能,并证实甲状腺大小与年龄和体型相关。
研究设计与样本
- 研究为前瞻性队列的横断面基线分析,纳入2016年4月1日至2021年12月31日在京都大学医院先制医学与生活习惯病研究中心接受首次综合体检的成人。
- 所有参与者均接受甲状腺功能检查、超声和FDG-PET,部分参与者测量了抗甲状腺过氧化物酶抗体(TPOAb)滴度。
- 分析纳入4407名无已知甲状腺疾病的参与者(2643名男性和1764名女性),其中2420名有TPOAb测量值,1840名无任何甲状腺异常者用于建立参考范围。
主要发现
- 在4407名参与者中,甲状腺功能障碍、超声血流增加、弥漫性甲状腺FDG摄取和甲状腺结节的患病率分别为5.8%、2.5%、3.4%和39.7%,所有异常在女性中均更常见。
- 在2420名有TPOAb测量值的参与者中,TPOAb阳性率为7.2%。
- 在Roche Elecsys平台上,TPOAb滴度≥128 IU/mL与并发甲状腺功能障碍、血流增加和弥漫性甲状腺FDG摄取相关。
- 多变量分析确定年龄、性别和甲状腺体积为甲状腺功能的主要决定因素。
- 利用1840名无任何甲状腺异常参与者的数据,建立了性别特异性甲状腺尺寸参考范围,并发现其与年龄和体型相关。
关键数值与推荐
- 甲状腺功能障碍患病率5.8%,超声血流增加2.5%,弥漫性甲状腺FDG摄取3.4%,甲状腺结节39.7%。
- TPOAb阳性率7.2%。
- TPOAb滴度≥128 IU/mL(Roche Elecsys平台)与并发甲状腺功能障碍、血流增加和弥漫性FDG摄取相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thyroid diseases can be evaluated using multiple modalities, including thyroid function tests, thyroid autoantibodies, ultrasonography, and 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET). However, comprehensive data integrating these modalities in large cohorts remain limited. We aimed to characterize the prevalence and patterns of abnormal findings on thyroid examinations in a medical checkup setting. METHODS: This was a cross-sectional baseline analysis of a prospective cohort of adults who underwent their initial comprehensive medical checkups between April 1, 2016, and December 31, 2021, at the Preemptive Medicine and Lifestyle Disease Research Center, Kyoto University Hospital. All participants underwent thyroid function tests, ultrasonography, and FDG-PET; anti-thyroperoxidase antibody (TPOAb) titers were measured in a subset. RESULTS: Among 4407 participants without known thyroid disease (2643 males and 1764 females), the prevalence of thyroid dysfunction, increased blood flow on ultrasonography, diffuse thyroid FDG uptake, and thyroid nodules was 5.8%, 2.5%, 3.4%, and 39.7%, respectively; all were more frequent in females. Among 2420 participants with TPOAb measurements, TPOAb positivity was 7.2%. On the Roche Elecsys platform, TPOAb titers ≥128 IU/mL were associated with concurrent thyroid dysfunction, increased blood flow, and diffuse thyroid FDG uptake. Multivariate analyses identified age, sex, and thyroid volume as major determinants of thyroid function. Using data from 1840 participants without any thyroid abnormalities, we established sex-specific reference ranges for thyroid dimensions and found their correlations with age and body size. CONCLUSIONS: This analysis provides epidemiological and physiological insights into thyroid health by integrating findings from thyroid function tests, ultrasonography, FDG-PET, and TPOAb measurements. Notably, higher TPOAb titers were associated with concurrent thyroid dysfunction and abnormalities, and age, sex, and thyroid volume were identified as major determinants of thyroid function. The rigorously defined healthy cohort enabled the establishment of sex-specific reference ranges for thyroid dimensions and confirmed associations between thyroid size, age, and body size. This study provides valuable evidence from a Japanese population, for which data have been limited to date. Furthermore, the present study highlights the associations among abnormal findings, relationships within thyroid physiology, and the concurrent associations of high-titer TPOAb with thyroid dysfunction and abnormalities.
引用
- Shimazu-Kuwahara S, Yamauchi I, Kawashima S, et al. Comprehensive Thyroid Assessment in a Prospective Japanese Cohort: A Cross-Sectional Baseline Analysis of Thyroid Function, Autoimmunity, and Ultrasonographic Findings. Thyroid. 2026. PMID: 43010676. doi:10.1177/10507256261504547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。